CFTR and cystic fibrosis: Our findings implicate polymicrobial interactions, rather than individual species abundance, in determining microbial persistence and adaptation within the CF airway post-ETI.IMPORTANCEThe introduction of the latest cystic fibrosis transmembrane conductance regulator (CFTR)-targeted Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy represents a major therapeutic advance for persons with cystic fibrosis (pwCF); however, this therapy does not completely negate respiratory infections and colonization.